Understand any stock in simple English
Enter a ticker to learn what the company does and how it makes money.
Viva Biotech helps drug companies discover and manufacture new medicines, mostly by studying the 3D shape of proteins and then making the molecules for testing and production.
Viva Biotech is a drug-discovery and manufacturing partner for the biotech industry. When a small biotech startup has a promising idea but no labs or chemists of its own, Viva steps in: it studies the shape of the protein the drug is meant to hit, designs molecules that fit it, tests them, and then makes the actual drug substance at larger scale. The company sits in the unglamorous middle of medicine-making — the part between a scientist's idea and a pill in a bottle.
The business rests on structure-based drug discovery, which simply means using the precise 3D shape of a disease-related protein to design a molecule that locks into it like a key in a lock. Viva built its reputation on this protein-structure work, serving biotech and pharmaceutical customers around the world from its base in China. It later pushed downstream into contract development and manufacturing, so it can now carry a customer's molecule from early lab research all the way toward production — a one-stop shop rather than a single-service vendor. That expansion came largely through acquisitions of manufacturing and chemistry capabilities, which turned Viva from a research specialist into a broader services group. The appeal to customers is speed and cost: outsourcing discovery and manufacturing lets small drugmakers stay lean and focus on their science, while Viva absorbs the heavy spending on labs, equipment, and skilled staff.
The catch is that this is a cyclical, competitive, and capital-hungry business. Viva competes with much larger global contract research and manufacturing players, and its fortunes swing with how much cash biotech companies can raise to fund early-stage research. When funding for young drugmakers dries up, orders slow — a vulnerability that has hit the whole sector. Viva also carries debt from its buildout, making cash flow and balance-sheet discipline central to the story.
Saved answer · last researched 15 Nov 2026